Opinion
Video
Key Highlights From ASH 2023
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.
The group discusses anticipated data on Bruton tyrosine kinase (BTK) inhibitors presented at the 2023 American Society of Hematology (ASH) annual meeting. Dr Jacobs highlights the updated results from the ALPINE trial comparing zanubrutinib to ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). The initial late-breaking results presented at ASH 2022 showed zanubrutinib had an improved safety profile and progression-free survival benefit over ibrutinib. The updated 1-year follow-up data presented at ASH 2023 confirm this progression-free survival difference has been maintained.
Dr Jacobs notes this updated data help reaffirm the efficacy differences seen between the next-generation BTK inhibitors like zanubrutinib and the original BTK inhibitor ibrutinib. ASH provides an opportunity to see the latest clinical trial results with these novel agents and how they may change treatment approaches for diseases like CLL and small lymphocytic lymphoma going forward.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
